Gentofte, Denmark

Louise Inoka Lyhne-Iversen

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 7.6

ph-index = 4

Forward Citations = 52(Granted Patents)


Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Louise Inoka Lyhne-Iversen

Introduction

Louise Inoka Lyhne-Iversen is a prominent inventor based in Gentofte, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly in developing compositions that are resistant to abuse. With a total of 6 patents to her name, her work has garnered attention for its potential impact on public health and safety.

Latest Patents

Among her latest innovations are pharmaceutical compositions designed for oral administration that are resistant to abuse. These immediate-release formulations aim to mitigate the risks associated with misuse, showcasing her commitment to creating safer medical solutions. The focus on abuse-resistant compositions highlights the growing need for responsible pharmaceutical development.

Career Highlights

Louise has established herself as a key figure in the pharmaceutical industry through her work at Egalet Ltd. Her expertise and innovative mindset have led to the development of groundbreaking products that address critical health issues. Her contributions are not only valuable to her company but also to the broader medical community.

Collaborations

Throughout her career, Louise has collaborated with notable professionals in her field, including Jan Martin Oevergaard and Karsten Lindhardt. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality and impact of her inventions.

Conclusion

In summary, Louise Inoka Lyhne-Iversen is a trailblazer in pharmaceutical innovation, with a focus on creating safer drug formulations. Her work exemplifies the importance of responsible invention in the medical field, and her contributions will likely continue to influence future developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…